Sai Life Sciences Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹31,787 Cr
- P/E
- 86.45
- ROE
- 15.42%
- PEG
- 0.37
- Price to sales
- 14.12
- Debt to equity
- 0.12
- 52W high / low
- ₹1,675 / ₹795
- Sales growth (5Y)
- 23.61%
- EBITDA margin
- 29.25%
- Net profit margin
- 16.22%
- Promoter holding
- 34.50%
- Sales (last year)
- ₹2,250 Cr
Incorporated in 1999, Sai Life Sciences Ltd carries out contract research and manufacturing activities for customers engaged in pharmaceutical and bio technology industries[1]
Guidance scorecard · Q1 FY27 call
What Sai Life Sciences Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
10–20%- Sai Life Sciences projects a long-term revenue growth guidance of 15% to 20% over a 3-to-5-year horizon.
- The company reported a 30% annualized growth last year, indicating strong momentum.
- Growth is expected despite inherent business lumpiness, with a plan to balance capacity expansion and technology investment.
- The CDMO business anticipates better performance in the second half of FY27, driven by new capacity coming online.
- Expanded collaborations via dedicated FTE development contracts and integrated service models with large pharma are expected to deepen customer relationships and pipeline.
2 more points from Sai Life Sciences Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Sai Life Sciences Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- A significant greenfield peptide manufacturing facility near Hyderabad is planned, expected operational by 2028.
- Investment in building pilot scale conjugation facilities for ADCs is underway, spanning discovery and development stages.
- New capacity is being developed for early to mid-stage deliveries at a new greenfield manufacturing site.
- Formulation capabilities are being added, with the facility expected operational within six months, driven by customer interest.
- Expansion includes two production blocks (225 KL each) in Bidar, totaling 450 KL, with the first block on track for H2 FY27.
2 more points from Sai Life Sciences Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Sai Life Sciences Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
- Sai Life Sciences Limited has a healthy order book supported by a growing base of large pharmaceutical customers.
- Over 90% of revenue in FY25 and FY26 came from returning customers, reflecting strong repeat orders.
- The company secured six late-phase molecules to its pipeline in the past 15 months, five of which came through large pharma clients with ongoing FTE (Full-Time Equivalent) engagements.
- Dedicated FTE development contracts are expected to augment the pipeline of late-phase and commercial molecules.
- One large pharma collaboration has expanded into a sizable dedicated FTE contract, covering the complete product lifecycle from discovery to commercial manufacturing.
- The discovery capacity expansion facility came on stream in Q1 and is already sold out, indicating strong demand.
2 more points from Sai Life Sciences Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Sai Life Sciences Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Sai Life Sciences Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Sai Life Sciences Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 384 | 439 | 280 | 396 | 440 | 580 | 496 | 537 | 556 | 602 |
| Expenses + | 287 | 315 | 254 | 293 | 320 | 422 | 375 | 392 | 369 | 426 |
| Operating Profit | 96 | 125 | 26 | 102 | 120 | 158 | 121 | 146 | 188 | 177 |
| OPM % | 25% | 28% | 9% | 26% | 27% | 27% | 24% | 27% | 34% | 29% |
| Other Income + | 11 | 3 | 8 | 10 | 9 | 10 | 10 | 15 | 0 | 16 |
| Interest | 23 | 21 | 21 | 21 | 23 | 11 | 12 | 9 | 10 | 8 |
| Depreciation | 31 | 31 | 31 | 36 | 34 | 37 | 38 | 40 | 44 | 45 |
| Profit before tax | 53 | 76 | -18 | 55 | 72 | 119 | 81 | 112 | 134 | 139 |
| Tax % | 25% | 26% | -25% | 25% | 25% | 26% | 25% | 25% | 25% | 25% |
| Net Profit + | 40 | 56 | -14 | 42 | 54 | 88 | 60 | 84 | 100 | 104 |
| EPS in Rs | 2.59 | 4.24 | 2.90 | 4.00 | 4.75 | 4.92 |
Financials of Sai Life Sciences Ltd
Profit & Loss
Annual income statement trend
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 695 | 726 | 760 | 870 | 1,217 | 1,465 | 1,695 | 2,192 |
| Expenses + | 520 | 558 | 593 | 743 | 1,048 | 1,178 | 1,285 | 1,561 |
| Operating Profit | 176 | 168 | 167 | 126 | 169 | 287 | 410 | 631 |
| OPM % | 25% | 23% | 22% | 15% | 14% | 20% | 24% | 29% |
| Other Income + | 6 | 18 | 27 | 28 | 27 | 29 | 35 | 41 |
| Interest | 24 | 22 | 33 | 54 | 81 | 88 | 78 | 39 |
| Depreciation | 44 | 55 | 80 | 90 | 99 | 119 | 139 | 167 |
| Profit before tax | 113 | 109 | 82 | 10 | 16 | 109 | 228 | 466 |
| Tax % | 35% | 30% | 25% | 36% | 39% | 24% | 25% | 25% |
| Net Profit + | 73 | 76 | 61 | 6 | 10 | 83 | 170 | 349 |
| EPS in Rs | 8.16 | 16.48 | ||||||
| Dividend Payout % | 0% | 0% | 0% | 1,117% | 676% | 0% | 0% | 0% |
Financials of Sai Life Sciences Ltd
Balance Sheet
Capital structure and asset base
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 17 | 18 | 18 | 18 | 21 | 21 |
| Reserves | 703 | 778 | 845 | 861 | 870 | 957 | 2,108 | 2,463 |
| Borrowings + | 249 | 304 | 637 | 752 | 933 | 928 | 352 | 288 |
| Other Liabilities + | 247 | 312 | 318 | 527 | 358 | 359 | 665 | 854 |
| Total Liabilities | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,626 |
| Fixed Assets + | 373 | 641 | 701 | 751 | 1,037 | 1,180 | 1,488 | 1,815 |
| CWIP | 116 | 91 | 246 | 410 | 151 | 107 | 124 | 270 |
| Investments | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 50 |
| Other Assets + | 726 | 679 | 870 | 997 | 989 | 973 | 1,531 | 1,490 |
| Total Assets | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,626 |
Financials of Sai Life Sciences Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 129 | 116 | -36 | 105 | 219 | 263 | 314 | 509 |
| Cash from Investing Activity + | -158 | -262 | -260 | -102 | -99 | -191 | -536 | -395 |
| Cash from Financing Activity + | 268 | -4 | 296 | 72 | -201 | -95 | 301 | -124 |
| Net Cash Flow | 239 | -150 | -1 | 75 | -80 | -24 | 79 | -10 |
| Free Cash Flow | -28 | -157 | -298 | -102 | 148 | 82 | -55 | -83 |
| CFO/OP | 90% | 81% | -13% | 90% | 132% | 96% | 82% | 87% |
Financials of Sai Life Sciences Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 123 | 136 | 99 | 102 | 85 | 64 | 76 | 62 |
| Inventory Days | 86 | 79 | 127 | 179 | 121 | 72 | 93 | 97 |
| Days Payable | 207 | 258 | 230 | 279 | 180 | 113 | 253 | 182 |
| Cash Conversion Cycle | 1 | -43 | -4 | 2 | 25 | 22 | -83 | -24 |
| Working Capital Days | 55 | 24 | 62 | 42 | 36 | 12 | 66 | 78 |
| ROCE % | 13% | 9% | 3% | 6% | 11% | 14% | 20% |
Guidance history
How Sai Life Sciences Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 10–20% | Flat | Planned | — | — |
| Q4 FY26 call → | 10–20% | Flat | Planned | Planned | — |
| Q3 FY26 call → | 10–20% | Flat | Planned | — | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
86 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +63.2% | 88% |
| Last 6 months | +39.9% | 85% |
| Last 3 months | +13.7% | 82% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Sai Life Sciences Ltd: 0.4 × 88 + 0.4 × 85 + 0.2 × 82 = 86.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Sai Life Sciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY